Custom Manufacturing, Project Outsourcing, your Trusted Partner from China
The landscape of Acute Myeloid Leukemia (AML) treatment is continuously evolving, driven by the pursuit of better patient outcomes and reduced relapse rates. For individuals diagnosed with intermediate-to-low-risk AML, achieving and maintaining remission is the primary goal. In this context, the combination of Venetoclax (VEN) and Azacitidine (AZA) has emerged as a promising strategy, with NINGBO INNO PHARMCHEM CO.,LTD. contributing essential pharmaceutical intermediates for its synthesis.
The efficacy of VEN-AZA therapy extends beyond initial remission. Studies are increasingly focusing on the role of maintenance therapy in preventing disease recurrence. For patients with intermediate risk AML, a significant finding has been the demonstrably lower relapse rate when maintenance therapy with VEN-AZA is employed. This implies a more durable response and potentially a longer period free from the disease's progression.
Similarly, for those with low risk AML, the application of maintenance therapy is being explored to solidify remission and prevent relapse. The concept behind this approach is to continuously suppress any lingering leukemic cells that might otherwise proliferate. This proactive strategy is a critical component of modern cancer care, moving from solely treating active disease to actively preventing its return.
The journey of cancer treatment often involves managing adverse events. Understanding the venetoclax azacitidine adverse events profile is vital for clinicians and patients alike. While certain side effects like myelosuppression are expected, the overall tolerability and manageable nature of these events in the context of improved survival outcomes are key considerations. NINGBO INNO PHARMCHEM CO.,LTD. is dedicated to supplying intermediates that meet the highest purity standards, supporting the development of treatments that are both effective and as safe as possible.
The ultimate aim is to improve the survival rates and quality of life for AML patients. Achieving MRD negative status after treatment is a strong predictor of favorable long-term outcomes. The continuous action of VEN-AZA therapy may play a role in achieving and maintaining this deeper level of remission. As research progresses, the role of pharmaceutical intermediates in these advanced therapies remains indispensable. NINGBO INNO PHARMCHEM CO.,LTD. stands ready to support the pharmaceutical industry in these critical endeavors.
Manufacturing Facilities
Professional Export Experience
to Global Customers
1. 20 years of R&D, manufacturing and sales experience, serving customers in 60 countries and regions around the world;
2. Own R&D laboratory, pilot platform and large-scale production workshop, which can meet the audit requirements of global customers;
3. We can satisfy customers' perfect transition from small scale lab requirements (gram level) to commercialization requirements (hundred tons level).
A: We don't have Minimum Order Quantity, exact quantity should be provided before quotation for us to calculate the exact cost.
A: We don't provide free samples due to lots of request and expensive international courier's cost, we can deduct the sample charge after commercial order placed.
A: Our payment terms: Small or sample order: T/T IN ADVANCE. Commercial order: First order should be by T/T IN ADVANCE or L/C at sight, and following orders T/T 30~90days is acceptable subject to approval of credit application.
